Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders, particularly myeloproliferative neoplasms, a group of blood cancers in which the bone marrow overproduces blood cells. It is headquartered in Waltham, Massachusetts, and has operations in Denmark and North America.

Its lead program, DMR-001, is an investigational monoclonal antibody that targets mutated calreticulin, known as mutCALR, a cancer-driving protein found in many patients with essential thrombocythemia and myelofibrosis. Follow-on programs DMR-002 and DMR-003 are mutCALR-directed therapies intended to address a broader range of patients with these mutations.

The company also holds GB3226, a small-molecule inhibitor of the ENL-YEATS and FLT3 targets being developed for acute myeloid leukemia. Its ordinary shares trade on Nasdaq under the ticker DMRA.